Sign In
Buy RXRX
$3.22
+0.0400 (+1.26%)
At Close: Aug 07, 2026
RXRX Q2 Earnings Miss Estimates, Revenues Fall Y/Y, Stock Down
12:01pm, Thursday, 06'th Aug 2026
Recursion misses Q2 earnings and revenue estimates as collaboration revenues fall year over year, sending shares lower while pipeline and partnership programs advanced.
Recursion Pharmaceuticals Q2 Earnings Call Highlights
03:04pm, Wednesday, 05'th Aug 2026
Recursion Pharmaceuticals NASDAQ: RXRX outlined progress across its clinical pipeline, drug-discovery partnerships and AI-enabled research platform, while lowering its 2026 cash operating expense guid
Recursion Pharmaceuticals, Inc. (RXRX) Q2 2026 Earnings Call Transcript
12:40pm, Wednesday, 05'th Aug 2026
Recursion Pharmaceuticals, Inc. (RXRX) Q2 2026 Earnings Call Transcript
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Misses Revenue Estimates
08:46am, Wednesday, 05'th Aug 2026
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.41 per share a year ago.
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
06:30am, Wednesday, 05'th Aug 2026
Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated tar
Recursion to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 04'th Aug 2026
Salt Lake City, UT, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
04:30pm, Friday, 31'st Jul 2026
Salt Lake City, UT, July 31, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on July 27, 2026, t
3 Stocks With the Most Upside by the End of 2026
04:30pm, Thursday, 30'th Jul 2026
Analysts remain optimistic that the market will view upcoming catalysts in a bullish light.
Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
06:46pm, Wednesday, 29'th Jul 2026
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $2.97, representing a -2.62% change from its previous close.
Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
08:30am, Wednesday, 29'th Jul 2026
Salt Lake City, UT, July 29, 2026 (GLOBE NEWSWIRE) -- Salt Lake City, UT, July 29, 2026 (GLOBE NEWSWIRE) – Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radi
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider
06:51pm, Monday, 27'th Jul 2026
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $3.01, denoting a +1.69% move from the preceding trading day.
A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed
Amova Asset Management Americas Inc. Sells 801,804 Shares of Recursion Pharmaceuticals, Inc. $RXRX
03:16am, Tuesday, 21'st Jul 2026
Amova Asset Management Americas Inc. decreased its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) by 12.9% during the undefined quarter, according to its most recent filing with
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know
06:51pm, Monday, 20'th Jul 2026
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $2.89, denoting a -1.87% move from the preceding trading day.
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today
06:51pm, Tuesday, 14'th Jul 2026
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.34, indicating a +1.21% shift from the previous trading day.
